Comments
Loading...

Panbela Therapeutics

PBLAOTCQB
Logo brought to you by Benzinga Data
$1.11
At close: Nov 22, 3:45 PM EDT

Panbela Therapeutics (OTC:PBLA) Stock, Earnings Estimates, EPS, And Revenue

Panbela Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.

Earnings Date
Nov 14
EPS
$-1.480
Quarterly Revenue
$0K
Annual Revenue
(as of Sep 30)

Analyze the earnings history of Panbela Therapeutics using advanced sorting and filters.

Data brought to you by Benzinga APIs

Panbela Therapeutics (PBLA) Earnings Per Share

Quarterly Earnings Surprise Amount

Fiscal Quarter EndDate ReportedActual EPSEstimated EPSSurprise %
Jun 20242024-08-13$-1.47$-1.6913.0 %
Mar 20242024-05-15$-2.28$-1.48-54.0 %
Dec 20232024-03-26$-65.90$-24.34-170.8 %
Sep 20232023-11-09$-2.42$-2.06-17.4 %

Panbela Therapeutics (PBLA) Revenue

Quarterly Revenue Surprise Amount

Fiscal Quarter EndDate ReportedActual RevenueEstimated RevenueSurprise %

FAQ

Q

When is Panbela Therapeutics (OTCQB:PBLA) reporting earnings?

A

Panbela Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3.

Q

What were the latest earnings per share (EPS) for Panbela Therapeutics (OTCQB:PBLA)?

A

Panbela Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was $-1.48, which missed the estimate of $0.00.

Q

What were Panbela Therapeutics’s (OTCQB:PBLA) revenues?

A

Panbela Therapeutics ({quoteSymbol}) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 14, 2024 for Q3 and the Actual EPS was {{actualEPS}}, which hit the estimate of {{estEPS}}.

Browse earnings estimates, EPS, and revenue on all stocks.